Intracranial ganglioglioma WHO I: results in a series of eight patients treated with stereotactic interstitial brachytherapy

详细信息    查看全文

• 作者：Faycal El Majdoub (1) (2)
  Essam Rezk (2)
  Stefan Hunsche (1) (2)
  Christian Bührle (2)
  Volker Sturm (2) (3)
  Mohammad Maarouf (1) (2)
  
• 关键词：Stereotactic interstitial brachytherapy ; Iodine ; 125 ; Ganglioglioma WHO I
• 刊名：Journal of Neuro-Oncology
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：118
• 期：2
• 页码：345-350
• 全文大小：
• 参考文献：1. Brainer-Lima PT, Brainer-Lima AM, Azevedo-Filho HR (2006) Ganglioglioma: comparison with other low-grade brain tumors. Arq Neuropsiquiatr 64(3A):613-18 CrossRef
  2. Brat DJ, Parisi JE, Kleinschmidt-DeMasters BK, Yachnis AT, Montine TJ, Boyer PJ, Powell SZ, Prayson RA, McLendon RE (2008) Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med 132(6):993-007. doi:10.1043/1543-2165(2008)132[993:SNUARO]2.0.CO;2
  3. Zhang D, Henning TD, Zou LG, Hu LB, Wen L, Feng XY, Dai SH, Wang WX, Sun QR, Zhang ZG (2008) Intracranial ganglioglioma: clinicopathological and MRI findings in 16 patients. Clin Radiol 63(1):80-1. doi:10.1016/j.crad.2007.06.010 CrossRef
  4. Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J (2004) Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8?years. Cancer 101(1):146-55. doi:10.1002/cncr.20332 CrossRef
  5. Adachi Y, Yagishita A (2008) Gangliogliomas: characteristic imaging findings and role in the temporal lobe epilepsy. Neuroradiology 50(10):829-34. doi:10.1007/s00234-008-0410-x CrossRef
  6. Compton JJ, Laack NN, Eckel LJ, Schomas DA, Giannini C, Meyer FB (2012) Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic. J Neurosurg 117(5):825-30. doi:10.3171/2012.7.JNS111260 CrossRef
  7. Matsumoto K, Tamiya T, Ono Y, Furuta T, Asari S, Ohmoto T (1999) Cerebral gangliogliomas: clinical characteristics, CT and MRI. Acta Neurochirurgica 141(2):135-41 CrossRef
  8. El Majdoub F, Elawady M, Blau T, Buhrle C, Hoevels M, Runge M, Muller RP, Deckert M, Sturm V, Maarouf M (2012) Intracranial ependymoma: long-term results in a series of 21 patients treated with stereotactic (125)iodine brachytherapy. PLoS ONE 7(11):e47266. doi:10.1371/journal.pone.0047266 CrossRef
  9. Maarouf M, El Majdoub F, Buhrle C, Voges J, Lehrke R, Kocher M, Hunsche S, Treuer H, Sturm V (2010) Pineal parenchymal tumors. Management with interstitial iodine-125 radiosurgery. Strahlentherapie und Onkologie 186 (3):127-34. doi:10.1007/s00066-010-2096-3
  10. Sturm V, Pastyr O, Schlegel W, Scharfenberg H, Zabel HJ, Netzeband G, Schabbert S, Berberich W (1983) Stereotactic computer tomography with a modified Riechert–Mundinger device as the basis for integrated stereotactic neuroradiological investigations. Acta Neurochir (Wien) 68(1-):11-7 CrossRef
  11. Koot RW, Maarouf M, Hulshof MC, Voges J, Treuer H, Koedooder C, Sturm V, Bosch DA (2000) Brachytherapy: results of two different therapy strategies for patients with primary glioblastoma multiforme. Cancer 88(12):2796-802 CrossRef
  12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-280
  13. Engel J (1993) Surgical treatment of the epilepsies, 2nd edn. Raven Press, New York
  14. El Majdoub F, Brunn A, Berthold F, Sturm V, Maarouf M (2009) Stereotactic interstitial radiosurgery for intracranial Rosai–Dorfman disease. A novel therapeutic approach. Strahlentherapie und Onkologie 185(2):109-12. doi:10.1007/s00066-009-1911-1
  15. Ruge MI, Simon T, Suchorska B, Lehrke R, Hamisch C, Koerber F, Maarouf M, Treuer H, Berthold F, Sturm V, Voges J (2011) Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. J Clin Oncol 29(31):4151-159. doi:10.1200/JCO.2011.37.3381 CrossRef
  16. Hakim R, Loeffler JS, Anthony DC, Black PM (1997) Gangliogliomas in adults. Cancer 79(1):127-31 CrossRef
  17. Rumana CS, Valadka AB, Contant CF (1999) Prognostic factors in supratentorial ganglioglioma. Acta Neurochirurgica 141(1):63-8 (discussion 68-9) CrossRef
  18. Selvanathan SK, Hammouche S, Salminen HJ, Jenkinson MD (2011) Outcome and prognostic features in anaplastic ganglioglioma: analysis of cases from the SEER database. J Neurooncol 105(3):539-45. doi:10.1007/s11060-011-0615-4 CrossRef
  19. Schlegel U, Bode U (2003) Neuroonkologie: 71 Tabellen. 2. erw.Aufl. edn. Thieme, Stuttgart
  
• 作者单位：Faycal El Majdoub (1) (2)
  Essam Rezk (2)
  Stefan Hunsche (1) (2)
  Christian Bührle (2)
  Volker Sturm (2) (3)
  Mohammad Maarouf (1) (2)
  
  1. Department of Stereotaxy and Functional Neurosurgery, Hospital of Cologne-Merheim, University of Witten/Herdecke, Ostmerheimer Strasse 200, 51109, Cologne, Germany
  2. Department of Stereotaxy and Functional Neurosurgery, University Hospital of Cologne, 50937, Cologne, Germany
  3. Department of Neurosurgery, University Hospital of Würzburg, 97080, Würzburg, Germany
  
• ISSN：1573-7373

文摘

In this retrospective study we evaluated the efficacy of interstitial brachytherapy (IBT) using 125Iodine seeds (125I) for intracranial ganglioglioma WHO I. Between October 1994 and March 2010, eight patients (m/f?=?5/3, median age 30.4?years, age range 7-2.5?years) with intracranial ganglioglioma WHO I were treated with IBT using stereotactically implanted 125I seeds. The median follow-up time was 41.5?months (range 16.7-40.1?months). Prior to interstitial brachytherapy one patient underwent microsurgical resection for three times; seven patients were treated with IBT primarily. In all patients we implanted the 125I seeds stereotactically guided. The cumulative tumor surface dose ranged between 50 and 65?Gy (permanent implantation) and the median tumor volume was 5.6?ml (range 0.9-6?ml). After brachytherapy, follow-up MR imaging revealed complete remission in one patient, partial remission in three and stable disease in the remaining four patients. Five of eight patients presented with seizures were either seizure-free (1/5) or improved (4/5). Temporary treatment-related morbidity occurred in one patient only (headache, nausea/vomiting) and resolved completely under steroid medication after 4?weeks. No treatment-related mortality was observed. This study indicates that interstitial brachytherapy for the treatment of intracranial ganglioglioma WHO I is safe and provides a high rate of local tumor control. Due to the limited number of cases, it is not possible to conduct a rigorous statistical evaluation. Thus, larger numbers of patients are required.